What we do
Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes
RDX5791, a non-systemic NHE3 inhibitor for the treatment of fluid and sodium overload, shifts sodium excretion from urine to feces in healthy subjects
D.Charmot, J.W. Jacobs, A.G.Spencer, M.Raab, D.Rosenbaum
© 2013 Ardelyx® All rights reserved.